0001209191-20-063449.txt : 20201215 0001209191-20-063449.hdr.sgml : 20201215 20201215160117 ACCESSION NUMBER: 0001209191-20-063449 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201214 FILED AS OF DATE: 20201215 DATE AS OF CHANGE: 20201215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Valamehr Bahram CENTRAL INDEX KEY: 0001748177 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 201389575 MAIL ADDRESS: STREET 1: C/O FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT, STE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3535 GENERAL ATOMICS COURT STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 3535 GENERAL ATOMICS COURT STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-14 0 0001434316 FATE THERAPEUTICS INC FATE 0001748177 Valamehr Bahram C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121 0 1 0 0 Chief Development Officer Common stock 2020-12-14 4 M 0 25000 2.90 A 112211 D Common stock 2020-12-14 4 S 0 1813 95.8947 D 110398 D Common stock 2020-12-14 4 S 0 11765 96.6546 D 98633 D Common stock 2020-12-14 4 S 0 2946 97.6959 D 95687 D Common stock 2020-12-14 4 S 0 3148 98.7969 D 92539 D Common stock 2020-12-14 4 S 0 3822 99.7685 D 88717 D Common stock 2020-12-14 4 S 0 400 100.97 D 88317 D Common stock 2020-12-14 4 S 0 1006 102.063 D 87311 D Common stock 2020-12-14 4 S 0 100 102.75 D 87211 D Stock Option (right to buy) 2.90 2020-12-14 4 M 0 25000 D 2026-01-07 Common Stock 25000 41156 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Represents the weighted average sale price of shares sold ranging from $95.23 to $96.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Represents the weighted average sale price of shares sold ranging from $96.23 to $97.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Represents the weighted average sale price of shares sold ranging from $97.27 to $98.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Represents the weighted average sale price of shares sold ranging from $98.28 to $99.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Represents the weighted average sale price of shares sold ranging from $99.28 to $100.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Represents the weighted average sale price of shares sold ranging from $100.48 to $101.41 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Represents the weighted average sale price of shares sold ranging from $101.56 to $102.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. This option is fully vested. Not applicable. /s/ Cindy R. Tahl, as Attorney-in-Fact 2020-12-15